COMMUNIQUÉS West-GlobeNewswire

Digital Utilities Ventures Acquires Lifestyle Dock Company, and Expands Market Reach for Easy NanoVoid™ Technology
25/03/2025
Acquisition Provides Strategic East Coast Manufacturing Facility and Strengthens International Distribution Capabilities Key Highlights: Strategic Acquisition for Market Expansion : Digital Utilities Ventures (OTC: DUTV [...]
Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock
25/03/2025
WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten offering of 3, [...]
Roche Annual General Meeting 2025
25/03/2025
Shareholders approved all proposals of the Board of Directors Severin Schwan was re-elected as Chairman of the Board of Directors; all other Board members standing for election were confirmed 38th consecutive dividend [...]
Assemblée générale 2025 de Roche
25/03/2025
Adoption de toutes les propositions du Conseil d’administration Réélection de Severin Schwan à la présidence du Conseil d’administration ; confirmation de tous les autres membres du Conseil d’administration qui se sont [...]
NervGen Pharma to Host Virtual Investor Event
25/03/2025
Key opinion leaders and company management will discuss the current spinal cord injury treatment landscape and NervGen's Phase 1b/2a clinical trial evaluating NVG-291 in individuals with spinal cord injury VANCOUVER, [...]
Syncromune Appoints Zhihong Li, Ph.D., as Chief Regulatory Affairs Officer to Lead Global Regulatory Strategy for Novel Oncology Immunotherapies
25/03/2025
FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, March 25, 2025 (GLOBE NEWSWIRE) -- Syncromune ® Inc., a clinical-stage biopharmaceutical company developing SYNC-T, an in situ personalized immunotherapy platform [...]
Epilepsy Foundation of America Harnesses the “Power in Purple” for Special Awareness Day
25/03/2025
Purple Day® encourages education, support, and advocacy for the epilepsy community BOWIE, Md., March 25, 2025 (GLOBE NEWSWIRE) -- Join the Epilepsy Foundation of America for Purple Day® on March 26, 2025 to uplift the “ [...]
Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
25/03/2025
ACESOT-1051 trial evaluating WEE1 kinase inhibitor APR-1051 now enrolling patients in Cohort 5; open label safety and efficacy data expected H2 2025 Twice daily (BID) dosing regimen in ongoing ABOYA-119 trial expected [...]
TOMI Environmental Solutions, Inc. Partners with Pharma Biotech System Components to Enhance Disinfection Solutions
25/03/2025
FREDERICK, Md., March 25, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a leader in disinfection and decontamination solutions, today announced an OEM partnership with Pharma [...]
Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer
25/03/2025
– Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial responders. All participants with disease control experienced a reduction in all [...]
Eterna Therapeutics Changes Name to Ernexa Therapeutics to Reflect New Strategic Focus on Ovarian Cancer and Autoimmune Disease
25/03/2025
Ernexa Therapeutics embarks on new strategic direction, shifting the company’s focus from delivering a cell therapy platform to prioritizing product development New tagline to emphasize the company’s unwavering [...]
Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refractory Disease
25/03/2025
- U.S. Food and Drug Administration states that data from the ongoing OnPrime/GOG-3076 Phase 3 registrational trial could potentially support traditional approval - WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE [...]
NKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2025)
25/03/2025
SANTA ANA, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative [...]
SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization
25/03/2025
TAMPA, FL, March 25, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”) , a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value [...]
Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data
25/03/2025
Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer’s disease Simufilam continued to demonstrate an [...]
Morningside Ventures Makes Strategic Investment in Xealth to Accelerate Digital Health Ecosystem
25/03/2025
Strategic investment will further the creation of a digitally-enabled care delivery system, bringing digital interventions within clinician workflows and to specific populations BOSTON and SEATTLE, March 25, 2025 (GLOBE [...]
PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference
25/03/2025
Updated time slot of 11:00 AM CT on Friday, March 28, 2025 PRINCETON, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy [...]
Avadel Announces Publications in CNS Drugs Supplement Highlighting Key Clinical Issues for People with Narcolepsy and Their Clinicians
25/03/2025
DUBLIN, March 25, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the publication of six manuscripts [...]
Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET
25/03/2025
Luke Laffin, MD, Cleveland Clinic, to discuss latest data from the pivotal Advance-HTN and Launch-HTN clinical trials and the potential of lorundrostat in hypertension RADNOR, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- [...]

Pages